Kidney Cancer

October 19, 2020

The FDA is reviewing data from the phase 3 CheckMate-9ER trial, which showed that the combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

October 02, 2020

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.

September 29, 2020

The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.

September 25, 2020

The combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

September 25, 2020

Meredith R. Metcalf, MD, discusses recent research evaluating management of clinical T1a RCC in men and women.

September 23, 2020

Investigators also reported that a subgroup of patients with 1 or more target kidney lesions experienced kidney tumor reduction and other benefits from the combination treatment.

September 22, 2020

“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.

September 17, 2020

Renal mass biopsy should be used for patients in whom results would impact management decisions.

August 24, 2020

The combination improved overall survival versus sunitinib in patients with previously untreated advanced RCC.

August 19, 2020

Combination therapy is the first-line standard for metastatic renal cell carcinoma.

July 29, 2020

The novel HIF-2α inhibitor MK-6482 led to a decrease in the size of target lesions in almost 90% of patients with von Hippel-Lindau disease–associated renal cell carcinoma.

July 27, 2020

A study author said that “the long exposure [to immune checkpoint inhibitor therapy] results in challenging surgery.”

July 24, 2020

“It’s case dependent. For appropriately selected patients, partial nephrectomy is preferred," says one urologist.

July 20, 2020

The phase 3 CONTACT-03 trial is exploring the combination of the multikinase inhibitor and immunotherapy agent in patients with renal cell carcinoma after exposure to an immune-checkpoint inhibitor.

July 13, 2020

Minimally invasive surgery was associated with similar overall survival and disease-specific survival outcomes compared with open surgery in patients with early-stage kidney cancer.

May 29, 2020

When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.

January 18, 2019

Dr. Kutikov discuss several noteworthy studies about kidney cancer from 2018.

January 18, 2019

"2018 was an exciting and productive year for kidney cancer research," write Amr A. Elbakry, MBBCh, MSc, and Ketan K. Badani, MD.

December 03, 2018

Activating interferon stimulated gene factor 3 could be a new direction for treating clear cell renal cell carcinoma, according to a recent study.

December 03, 2018

“The efficacy benefit and the favorable safety profile support aveluamb plus axitinib as a new first-line standard of care for advanced RCC,” says researcher Robert J. Motzer, MD.